Garching / Munich, Germany – August 18, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it has signed an agreement to acquire ...

GARCHING, Germany & MUNICH--(BUSINESS WIRE)--ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Helmholtz Munich (Helmholtz Zentrum München), today announced ...

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc.

Garching / Munich, Germany, May 27, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a debt financing agreement for up to USD 262.5 ...

GARCHING / MUNICH, Germany and VANCOUVER, BC, Jan. 30, 2024 /PRNewswire/ -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a ...

Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 – ITM Isotope ...

MUNICH & GARCHING, Germany & CHALK RIVER, Ontario--(BUSINESS WIRE)--ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL), Canada’s ...